Please login to the form below

Not currently logged in
Email:
Password:

Dr Michael Watson appointed as president of Valera

Former Sanofi Pasteur policy head joins Moderna Therapeutics firm

Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president.

Dr Watson brings twenty years of vaccines expertise to the role and has broad experience in the development and licensing of vaccines for conditions such as smallpox, encephalitis and influenza.

Stéphane Bancel, chief executive officer of Moderna, said: “We are thrilled to have Mike assume the helm of Valera, particularly at this critical inflection point for the company, as we continue to progress our clinical stage infectious disease pipeline.”

He joins the infectious diseases specialty firm from Sanofi Pasteur, where he most recently served as its global head of vaccination policy and advocacy and has also held the position of head of clinical and epidemiology in France.

Prior to this, Dr Watson has been head of research and development at Acambis and Aventis Pasteur MSD's medical director for the UK.

He is currently a member of the Board of Vaccines Europe and The Foundation for Innovative New Vaccines.

Dr Watson said: “The potential for mRNA therapeutics to meaningfully address some of the world's most pressing infectious disease concerns is truly exciting.

“Moderna's technology, coupled with its goal to deliver transformative medicines to millions of patients, makes this an extraordinary opportunity.

“I am eager and proud to join Valera and work with this outstanding team and Moderna's esteemed infectious disease-focused partners.”

13th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics